Hepatitis C Virus
University of Michigan details research in hepatitis C virus
Published in Hepatitis Weekly, April 13th, 2009
"Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined. Week 0, 24, 48, and 72 serum samples were analyzed for YKL-40, tissue inhibitor of matrix metalloproteinase-1, amino-terminal peptide of type III procollagen (PIIINP), and hyaluronic acid (HA) levels," scientists writing in the journal Clinical Gastroenterology and Hepatology report.
"All 456 chronic hepatitis C (CHC) patients received peginterferon alfa 2a and ribavirin for 24 to 48 weeks. Mean age was 49.2 years, 71% were male, and 39% had cirrhosis. Lower pretreatment serum...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-04-13)
More Articles from Hepatitis Weekly
- World Journal of Gastroenterology
Mutations within a conservative region of HCV affects the therapy - Cytokines
Research from Emory University in the area of cytokines published - DNA Research
Research data from C.L. Netherton and colleagues update understanding of DNA research - Encephalomyelitis
Research from Fukui University yields new data on encephalomyelitis - Fibrosis
Research on fibrosis described by scientists at St. Louis University - Graft-Versus-Host Disease
Reports outline graft-versus-host disease research from S.B. Harvey and colleagues - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
